Today, Dr. Francesc Mitjans, Director of Health & Biomedicine at Leitat, is participating in the 2019 edition of the Drug Discovery Summit, taking place in Barcelona. He will present the capacities of Leitat regarding the discovery, development and characterization of oncological drugs, especially of monoclonal antibodies. He will also present Lykera, a spin-off of Leitat, and its assets, being 3 anti-cancer monoclonal antibodies and anti-metastasis for several types of solid tumors as well as their therapeutic efficacy and diagnostic application.
About the Drug Discovery Summit:
The Drug Discovery Summit (DDS) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange that will give all the participants the opportunity to share their experiences, foster collaborations across industry and academia and evaluate emerging technologies across the globe.